Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies

Affiliations

¹ Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA. drsusanbal@gmail.com.
² University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
³ University of Texas Southwestern Medical Center, Dallas, TX, USA.
⁴ Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.
⁵ Washington University in St. Louis, St Louis, MO, USA.
⁶ Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
⁷ Vanderbilt University, Nashville, TN, USA.
⁸ Duke University, Durham, NC, USA.
⁹ University of Vermont, Burlington, VT, USA.
¹⁰ Medical College of Wisconsin, Milwaukee, WI, USA.
¹¹ Stanford University, Stanford, CA, USA.
¹² University of Wisconsin, Carbone Cancer Center, Madison, WI, USA.
¹³ Department of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.

Susan Bal et al. Leukemia. 2022 Mar.

. 2022 Mar;36(3):877-880.

doi: 10.1038/s41375-021-01471-3. Epub 2021 Nov 20.

¹ Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA. drsusanbal@gmail.com.
² University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
³ University of Texas Southwestern Medical Center, Dallas, TX, USA.
⁴ Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.
⁵ Washington University in St. Louis, St Louis, MO, USA.
⁶ Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
⁷ Vanderbilt University, Nashville, TN, USA.
⁸ Duke University, Durham, NC, USA.
⁹ University of Vermont, Burlington, VT, USA.
¹⁰ Medical College of Wisconsin, Milwaukee, WI, USA.
¹¹ Stanford University, Stanford, CA, USA.
¹² University of Wisconsin, Carbone Cancer Center, Madison, WI, USA.
¹³ Department of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.

No abstract available

References

1. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–8. - DOI
1. Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997. - DOI
1. Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019. http://www.nature.com/articles/s41375-019-0435-7 .
1. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46. - DOI
1. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N. Engl J Med. 2019;380:1726–37. - DOI